Recombinant Mouse Map2k1 Protein, Myc/DDK-tagged

• Cat.No.: Map2k1-3920M
• Product Overview: Purified recombinant protein of mouse full-length mitogen-activated protein kinase kinase 1 (Map2k1), with C-terminal MYC/DDK tag, expressed in HEK293T cells.

Specification

• Description: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.
• Source: HEK293T
• Species: Mouse
• Tag: Myc&DDK
• Molecular Mass: 43.5 kDa
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: Store at -80 centigrade after receiving vials.
• Concentration: >50 μg/mL as determined by microplate BCA method
• Storage Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol.

Gene Information

• Gene Name: Map2k1 mitogen-activated protein kinase kinase 1 [ Mus musculus (house mouse) ]
• Official Symbol: Map2k1
• Synonyms: MAP2K1; mitogen-activated protein kinase kinase 1; dual specificity mitogen-activated protein kinase kinase 1; MEK 1; MAPKK 1; MAPK/ERK kinase 1; MAP kinase kinase 1; ERK activator kinase 1; mitogen activated protein kinase kinase 1; protein kinase, mitogen activated, kinase 1, p45; Mek1; MEKK1; MAPKK1; Prkmk1
• Gene ID: 26395
• mRNA Refseq: NM_008927
• Protein Refseq: NP_032953
• UniProt ID: P31938

Reviews

08/01/2020

The unmatched performance of the MAP2K1 protein in both ELISA assays and protein electron microscopy structure analysis showcases its versatility and reliability in various experimental settings.

05/18/2016

The MAP2K1 protein finds extensive utility in protein electron microscopy structure analysis.

04/11/2016

With its exceptional specificity and sensitivity, it enables precise and reliable detection of target molecules, making it a valuable tool in the field of diagnostic and research applications.

Q&As

Are there ongoing clinical trials targeting MAP2K1?

Yes, there are clinical trials exploring the efficacy and safety of MAP2K1 inhibitors in various cancers and other diseases.

Are there diagnostic tests specifically targeting MAP2K1 in clinical practice?

Some diagnostic tests may analyze MAP2K1 mutations, especially in the context of cancer, to inform treatment decisions.

What diagnostic applications does MAP2K1 have in cancer detection?

MAP2K1 mutations can serve as biomarkers in cancer diagnostics, aiding in the identification and classification of tumors.

How does MAP2K1 contribute to drug resistance in cancer treatment?

MAP2K1 mutations can be associated with resistance to certain cancer therapies, making it important to understand its role in treatment response.

Are there targeted therapies based on MAP2K1 in cancer treatment?

Yes, MAP2K1 inhibitors are being explored as targeted therapies in cancer treatment, aiming to block the abnormal signaling associated with MAP2K1 mutations.